Cellectis to Participate in Upcoming Investor Conferences

Published on September 04, 2017 in New York (N.Y.)

Back to all press releases

September 4, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Three of them will be webcasted live. The replay will be available in the Investor Relations section of the Company’s website at http://cellectis.com/en/investors/events-and-webcasts/

  • September 6, 2017, André Choulika, CEO of Cellectis, to present at the Wells Fargo Conference in Boston from 4:10 to 4:40pm ET

  • September 11, 2017, André Choulika to present at the Morgan Stanley Global Healthcare Conference in New York from 9:20 to 9:50am ET

  • September 26, 2017, André Choulika to present at the Ladenburg Thalmann 2017 Conference in New York from 2:00 to 2:25pm ET

  • September 28, 2017, André Choulika to present at the Leerink Rare Disease & Immuno-Oncology Conference in New York at 2:30 pm ET

Download the PDF file